A second late-stage Phase III study has demonstrated that a combination of Avastin and chemotherapy improves progression-free survival in women with ovarian cancer compared to chemotherapy alone.

The study, which involved 1,528 patients, met its primary endpoint by showing that the drug helped women with previously untreated ovarian cancer live longer without their disease getting worse.

Avastin became the first widely available anti-angiogenic therapy for the treatment of advanced cancer when it was given US approval for colorectal cancer in 2004.